Chief Legal Officer reports initial insider status at Vera Therapeutics (VERA)

Rhea-AI Filing Summary

Vera Therapeutics, Inc. filed an initial insider ownership report for Chief Legal Officer Jane Wright-Mitchell. This Form 3 establishes her status as an officer subject to insider reporting rules. The structured data provided shows no insider share transactions or derivative holdings reported in this filing.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Wright-Mitchell Jane

(Last) (First) (Middle)

C/O VERA THERAPEUTICS, INC.

2000 SIERRA POINT PARKWAY, SUITE 1200

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/23/2026

3. Issuer Name and Ticker or Trading Symbol
Vera Therapeutics, Inc. [ VERA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Joseph R. Young, Attorney-in-Fact	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Vera Therapeutics (VERA) disclose in this Form 3?

Vera Therapeutics discloses an initial insider ownership report for Chief Legal Officer Jane Wright-Mitchell. The filing establishes her as a reporting officer and shows no insider share transactions or derivative positions in the structured data.

Who is the reporting person in Vera Therapeutics (VERA) latest Form 3?

The reporting person is Jane Wright-Mitchell, Chief Legal Officer of Vera Therapeutics. She is identified as an officer, not a director or 10% owner, and becomes subject to ongoing insider reporting requirements under SEC rules.

Does the Vera Therapeutics (VERA) Form 3 show any insider share purchases or sales?

The structured data for this Form 3 shows no reported insider share purchases, sales, exercises, gifts, or tax-withholding transactions. All transaction counters, including buyCount and sellCount, are zero in the transaction summary.

Are there any derivative securities reported in the Vera Therapeutics (VERA) Form 3?

The derivativeSummary section in the structured data is empty, indicating no stock options, warrants, or other derivative holdings are listed for Jane Wright-Mitchell in this particular Form 3 filing excerpt.

What does the transaction summary indicate in Vera Therapeutics (VERA) Form 3?

The transaction summary indicates zero buys, zero sells, and no derivative exercises or gifts, with netBuySellDirection labeled neutral. This characterizes the filing as an administrative initial ownership report rather than a record of trading activity.